$96.49
5.29% yesterday
NYSE, Nov 19, 10:00 pm CET

Glaukos Corp Stock price

$96.49
+17.02 21.42% 1M
+0.64 0.67% 6M
-53.45 35.65% YTD
-47.72 33.09% 1Y
+49.22 104.13% 3Y
+28.16 41.21% 5Y
+70.88 276.77% 10Y
+65.27 209.06% 20Y
NYSE, Closing price Wed, Nov 19 2025
+4.85 5.29%

Key metrics

Basic
Market capitalization
$5.5b
Enterprise Value
$5.3b
Net debt
positive
Cash
$273.7m
Shares outstanding
57.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.8 | 11.0
EV/Sales
11.4 | 10.6
EV/FCF
negative
P/B
7.2
Financial Health
Equity Ratio
78.7%
Return on Equity
-19.1%
ROCE
-9.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$469.8m | $502.0m
EBITDA
$-49.5m | $-40.6m
EBIT
$-88.4m | $-59.2m
Net Income
$-87.6m | $-48.1m
Free Cash Flow
$-44.2m
Growth (TTM | estimate)
Revenue
30.4% | 30.9%
EBITDA
36.2% | 60.7%
EBIT
23.9% | 45.2%
Net Income
41.4% | 67.1%
Free Cash Flow
45.6%
Margin (TTM | estimate)
Gross
76.9%
EBITDA
-10.5% | -8.1%
EBIT
-18.8%
Net
-18.7% | -9.6%
Free Cash Flow
-9.4%
More
EPS
$-1.5
FCF per Share
$-0.8
Short interest
7.1%
Employees
995
Rev per Employee
$390.0k
Show more

Is Glaukos Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,037 stocks worldwide.

Glaukos Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Glaukos Corp forecast:

19x Buy
86%
2x Hold
9%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Glaukos Corp forecast:

Buy
86%
Hold
9%
Sell
5%

Financial data from Glaukos Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
470 470
30% 30%
100%
- Direct Costs 109 109
29% 29%
23%
361 361
31% 31%
77%
- Selling and Administrative Expenses 306 306
20% 20%
65%
- Research and Development Expense 143 143
5% 5%
31%
-49 -49
36% 36%
-11%
- Depreciation and Amortization 39 39
1% 1%
8%
EBIT (Operating Income) EBIT -88 -88
24% 24%
-19%
Net Profit -88 -88
41% 41%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Glaukos Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Glaukos Corp Stock News

Neutral
Seeking Alpha
9 days ago
Glaukos Corporation ( GKOS ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Alex Thurman - Senior VP & CFO Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Good morning...
Negative
The Motley Fool
14 days ago
Baltimore-based Brown Capital Management sold 376,359 shares of Glaukos Corporation for an estimated $34.6 million in the third quarter. The transaction value equaled approximately 1.4% of fund's 13F assets under management at quarter-end.
Neutral
Business Wire
17 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 1...
More Glaukos Corp News

Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Head office United States
CEO Thomas Burns
Employees 995
Founded 1998
Website www.glaukos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today